Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 86.39%
As of Friday, October 30, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 86.39%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. ABOS
$0.21
0.00
-2.03%
November 5, 2026 1:15:47 PM
EST
Volume: 5,156,641
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Commentary & Analysis
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Up 5.97%
As of Wednesday, October 28, Acumen Pharmaceuticals, Inc.’s ABOS share price has surged by 5.97%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 5.51%
As of Tuesday, October 27, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Michael Rose
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 6.55%
As of Friday, October 23, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 6.55%, which has investors questioning if this is right time to buy.Michael Rose
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Up 9.89%
As of Tuesday, October 20, Acumen Pharmaceuticals, Inc.’s ABOS share price has surged by 9.89%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.6 | $227.3 | 9% |
|
| Shares Out (Mil) | 72.3 | 53.4 | 56% |
|
| Institutional Ownership | 70.4% | 92.9% | 43% |
|
| Float (Mil) | 37.1 | 41.4 | 40% |
|
| Beta | 0.33 | 0.95 | 19% |
|
| Avg Daily Volume (000s) | 12,332 | 468 | 97% |
|
| Price Change (52-week) |
(90.1%) | 47.4% | 5% |
|
| Growth | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (75.4%) | (10.1%) | 3% |
|
| EPS (5yr) | 35.2% | 15.8% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (68.0%) | (15.7%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.453) | ($1.609) | ($0.486) | |
| Month Ago EPS | ($0.400) | ($1.589) | ($1.433) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.447) | ($1.585) | ($1.507) | |
| Year/Year Chg | 29.1% | (19.7%) | (99.8%) | |
| Financials | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($104) | ($44) | 11% |
|
| EPS (TTM) | ($1.549) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $1 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $111 | $174 | 22% |
|
| Valuation | ABOS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.45 | 2.14 | 9% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (91.3%) | (47.1%) | 6% |
|
| ROE | (162.7%) | (52.0%) | 5% |
|
| Liabilities to Assets | 59.6% | 29.7% | 54% |
|
| F-Score | 2 | 2 | 7% |
|
Acumen Pharmaceuticals, Inc. did not pass any screens on 11/4/2026.
